| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The carboxylic acid group of AMCA provides a reactive site for conjugation to amines through carbodiimide-mediated coupling reactions or NHS ester formation. The compound does not target specific enzymes or receptors but serves as a fluorescent labeling reagent.
|
|---|---|
| ln Vitro |
AMCA is a fluorescent protein labeling agent that emits in the blue region (440-460 nm) upon activation with UV light (350 nm). The compound's NHS ester derivative reacts with lysine residues to form photostable amide links. The blue fluorescence provides distinct spectral properties for multiplexing with other fluorophores.
|
| ln Vivo |
No significant in vivo activity data has been reported for AMCA as a therapeutic agent, as the compound is primarily utilized as a fluorescent labeling reagent for research applications. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro labeling assays for AMCA involve converting the carboxylic acid to an NHS ester and incubating with amine-containing biomolecules. The NHS ester reacts with lysine residues to form photostable amide links. Labeling efficiency can be assessed by measuring the fluorescence intensity of the conjugated product.
|
| Cell Assay |
For in vitro cellular experiments, AMCA is conjugated to antibodies, proteins, or other targeting ligands via the carboxylic acid group or NHS ester. The labeled conjugates are then added to cell culture medium for incubation with target cells. After washing, cells are analyzed by fluorescence microscopy. The blue fluorescence is activated by UV light.
|
| Animal Protocol |
In vivo animal experiments with AMCA are not typically performed as a therapeutic intervention. However, the dye can be used for in vivo imaging applications when conjugated to targeting ligands. The blue fluorescence provides distinct spectral properties. Conjugates bearing AMCA can be administered to animal models for tracking biodistribution.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of AMCA have not been characterized, as the compound is a research-use fluorescent labeling reagent rather than a drug candidate. The compound has a molecular weight of 233.22 g/mol and a molecular formula of C₁₂H₁₁NO₄. It should be stored at room temperature in a cool and dark place.
|
| Toxicity/Toxicokinetics |
Toxicological data for AMCA has not been systematically evaluated, as the compound is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| References | |
| Additional Infomation |
7-Amino-4-methylcoumarin-3-acetic acid (AMCA) is a small-molecule blue fluorophore belonging to the aminocoumarin class. The compound serves as a foundational reagent for the synthesis of amine-reactive fluorescent probes via its NHS ester derivative. AMCA emits in the blue region (440-460 nm) upon activation with UV light (350 nm). The compound has no clinical or therapeutic applications and has not received regulatory approval.
|
| Molecular Formula |
C12H11NO4
|
|---|---|
| Molecular Weight |
233.22
|
| Exact Mass |
233.069
|
| CAS # |
106562-32-7
|
| PubChem CID |
129367
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.391g/cm3
|
| Boiling Point |
512.2ºC at 760mmHg
|
| Flash Point |
263.6ºC
|
| Vapour Pressure |
2.58E-11mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
1.891
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
388
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C(=O)OC2=C1C=CC(=C2)N)CC(=O)O
|
| InChi Key |
QEQDLKUMPUDNPG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H11NO4/c1-6-8-3-2-7(13)4-10(8)17-12(16)9(6)5-11(14)15/h2-4H,5,13H2,1H3,(H,14,15)
|
| Chemical Name |
2-(7-amino-4-methyl-2-oxochromen-3-yl)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (535.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2878 mL | 21.4390 mL | 42.8780 mL | |
| 5 mM | 0.8576 mL | 4.2878 mL | 8.5756 mL | |
| 10 mM | 0.4288 mL | 2.1439 mL | 4.2878 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
